TY - JOUR
T1 - Growth Factor Immobilization to Synthetic Hydrogels
T2 - Bioactive bFGF-Functionalized Polyisocyanide Hydrogels
AU - van Velthoven, Melissa J. J.
AU - Gudde, Aksel N.
AU - Arendsen, Evert
AU - Roovers, Jan-Paul
AU - Guler, Zeliha
AU - Oosterwijk, Egbert
AU - Kouwer, Paul H. J.
N1 - Funding Information: This project received public funding from ZonMw for the TOP project (grant number: 91218030). The authors acknowledge Dr. Roel Hammink for his input on the bFGF‐DBCO synthesis and Dr. Behrad Shaghaghi for helping with the polymer synthesis and characterization. Publisher Copyright: © 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2023/10/27
Y1 - 2023/10/27
N2 - With its involvement in cell proliferation, migration and differentiation basic fibroblast growth factor (bFGF) has great potential for tissue engineering purposes. So far, however, clinical translation of soluble bFGF-based therapies is unsuccessful, because the required effective doses are often supraphysiological, which may cause adverse effects. An effective solution is growth factor immobilization, whereby bFGF retains its bioactivity at increased efficacy. Studied carriers include films, solid scaffolds, and particles, as well as natural and synthetic hydrogels. However, these synthetic hydrogels poorly resemble the characteristics of the native extracellular matrix (ECM). In this work, bFGF is covalently conjugated to the synthetic, but highly biocompatible, polyisocyanide-based hydrogel (PIC-bFGF), which closely mimics the architecture and mechanical properties of the ECM. The growth factor conjugation protocol is straightforward and readily extrapolated to other growth factors or proteins. The PIC-bFGF hydrogel shows a prolonged bioactivity up to 4 weeks although no clear effects on the ECM metabolism are observed. Beyond the future potential of the PIC-bFGF hydrogel toward various tissue engineering applications, this work underlines that simple biological conjugation procedures are a powerful strategy to induce additional bioactivity in 3D synthetic cell culture matrices.
AB - With its involvement in cell proliferation, migration and differentiation basic fibroblast growth factor (bFGF) has great potential for tissue engineering purposes. So far, however, clinical translation of soluble bFGF-based therapies is unsuccessful, because the required effective doses are often supraphysiological, which may cause adverse effects. An effective solution is growth factor immobilization, whereby bFGF retains its bioactivity at increased efficacy. Studied carriers include films, solid scaffolds, and particles, as well as natural and synthetic hydrogels. However, these synthetic hydrogels poorly resemble the characteristics of the native extracellular matrix (ECM). In this work, bFGF is covalently conjugated to the synthetic, but highly biocompatible, polyisocyanide-based hydrogel (PIC-bFGF), which closely mimics the architecture and mechanical properties of the ECM. The growth factor conjugation protocol is straightforward and readily extrapolated to other growth factors or proteins. The PIC-bFGF hydrogel shows a prolonged bioactivity up to 4 weeks although no clear effects on the ECM metabolism are observed. Beyond the future potential of the PIC-bFGF hydrogel toward various tissue engineering applications, this work underlines that simple biological conjugation procedures are a powerful strategy to induce additional bioactivity in 3D synthetic cell culture matrices.
KW - basic fibroblast growth factor
KW - bioactivity
KW - growth factor immobilization
KW - polyisocyanide hydrogels
KW - tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=85167985274&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/adhm.202301109
DO - https://doi.org/10.1002/adhm.202301109
M3 - Article
C2 - 37526214
SN - 2192-2640
VL - 12
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 27
M1 - 2301109
ER -